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Acquired hemophilia A (AHA) and acquired von Willebrand Syndrome (AVWS) are both rare bleeding disorders that
can be associated with lymphoproliferative or autoimmune diseases. AHA is uniformly caused by inhibitory
autoantibodies against coagulation factor VIII (FVIII), while the pathophysiology of AVWS comprises several distinct
mechanisms, including reduced synthesis, accelerated clearance, or increased proteolysis. In this regard,
autoantibodies to von Willebrand factor (VWF) have been described in patients with systemic lupus erythematosus
(SLE) or monoclonal gammopathy. Here, we report the case of a 71-year-old patient with a recent onset of
spontaneous mucocutaneous and soft-tissue bleeding due to severely decreased FVIII and VWF. While there was
no evidence for monoclonal gammopathy, specific IgG antibodies against both FVIII and VWF were detected.
Furthermore, VWF multimer analysis revealed the presence of ultralarge plasma multimers and absence of the
typical multimeric triplet structure, a finding consistent with decreased proteolytic processing of massively released,
but rapidly cleared VWF. Both FVIII and VWF readily responded to immunosuppressive therapy with prednisolone.
Interestingly, clinical and laboratory findings established the diagnosis of “late-onset SLE” in our patient. Thus, about
45 years after the first description of AVWS in a 12-year-old boy with SLE, we present another unusual case of
concomitant autoimmune-mediated AHA and AVWS in an elderly SLE patient, which, to the best of our knowledge,
has not been reported so far.
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Ultralarge von Willebrand factor plasma multimersBackground
Acquired hemophilia A (AHA) and acquired von
Willebrand syndrome (AVWS) are rare bleeding dis-
orders. They both affect mostly elderly people and are as-
sociated with significant morbidity and mortality. While
AHA is uniformly caused by inhibitory autoantibodies
against coagulation factor VIII (FVIII), the pathophysio-
logy of AVWS comprises several distinct mechanisms.
These include, but are not limited to, reduced synthesis,
accelerated clearance due to circulating autoantibodies or
adsorption onto tumor cells or platelets, and increased* Correspondence: langer@uke.de
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unless otherwise stated.shear-dependent cleavage by ADAMTS13 or by other
more non-specific proteases such as plasmin. AVWS may
thus result from quantitative and/or qualitative abnormal-
ities of plasmaVWF [1].
Malignancy and autoimmune diseases are among the
most frequently reported underlying conditions in pa-
tients with AHA, but more than half of the cases remain
idiopathic. In contrast, virtually all cases of AVWS are
secondary to another disease, including hematological,
lymphoproliferative, cardiovascular, and autoimmune dis-
orders as well as hypothyroidism [2-4]. In this regard, it is
noteworthy that the first description of AVWS has been in
a boy suffering from systemic lupus erythematosus (SLE)
[5] with subsequent studies clearly implicating the pro-
duction of VWF autoantibodies in the pathogenesis of
SLE-associated AVWS [6-11].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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functions as a protective carrier protein for FVIII within
the circulation, which may at least theoretically serve as
the molecular basis for a common autoimmune reaction
against the VWF/FVIII complex, a case of concomitant
immune-mediated AHA and AVWS has not been previ-
ously reported.
Case presentation
A 71-year-old man was admitted to our hospital due to
recent onset of diffuse gum bleeding. Macroscopic he-
maturia and spontaneous bruises had also occurred one
month prior to the current presentation. A minor trauma
during physical exercise had led to an extensive hemar-
throsis of the left elbow. Previously, the patient had also
complained about recurrent skin rashes, myalgia, arthral-
gia, and fatigue. His prior medical history included arterio-
sclerosis, paresthesia of both legs of unknown etiology,
and asbestosis with no evidence for pleural mesothelioma.
His family history was negative for a bleeding diathesis,
and he did not take any medication.
On admission (day 0), coagulation tests revealed a
significantly prolonged activated partial thromboplastin
time (APTT) of 79 sec (normal range, 25-38 sec) with no
correction upon 1:1 (vol:vol) mixing of the patient with
normal human plasma. FVIII clotting activity (FVIII:C)
was reduced to 2% (normal range, 60-160%) [Figure 1]. A
Nijmegen-modified Bethesda and an enzyme-linked im-
munosorbent assay (ELISA) revealed a FVIII inhibitor of
4.6 Bethesda units (BU) (normal range, <0.5 BU) and 1.37
optical densities (OD) (normal plasma pool, 0.24 OD),Figure 1 Plasma levels of factor VIII clotting activity (FVIII:C) and von
presentation and during course of treatment. The first set of data point
second set of data points (d3) shows FVIII and VWF levels immediately befo
indicated by the dashed arrow. To assess incremental recovery and residen
drawn 15 min (d3´), 60 min (d3´´), and 120 min (d3´´´) after concentrate ad
prednisolone was started at a daily dose of 100 mg, which was gradually t
later, there was a steep decline in FVIII and VWF, both of which readily resprespectively. These findings clearly established the diagno-
sis of AHA.
However, further laboratory work-up revealed max-
imally prolonged closure times of >300 sec in the PFA-
100® (platelet function analyzer, Dade-Behring) using both
the collagen/epinephrine (normal range, 84-160 sec) and
the collagen/ADP cartridge (normal range, 68-121 sec),
which suggested severely impaired shear-dependent pri-
mary hemostasis. In addition, platelet agglutination in the
patient’s platelet-rich plasma induced by 1.2 or 1.5 mg/mL
ristocetin was dramatically reduced to 4% and 24%, re-
spectively (normal ranges, 60-95% and 75-100%, respect-
ively), further indicating a specific defect in plasma VWF.
Consistently, VWF antigen (VWF:Ag) was <3% (normal
range, 60-200%), and VWF activity (VWF:Ac), as deter-
mined by the INNOVANCE® GPIb binding assay (Siemens
Healthcare), was 4% (normal range, 61-179%) [Figure 1].
The ratio of the prothrombin time (INR, 0.93) and the
platelet count (206 × 103/μL) were normal.
Because severely decreased VWF parameters could not
be explained by the low-titer FVIII inhibitor, we used a
novel in-house ELISA to explore the concomitant pres-
ence of a VWF autoantibody [12]. Briefly, recombinant
human VWF (rhVWF) purified from culture supernatants
of transfected Chinese hamster ovary (CHO) cells was
bound to high binding ELISA plates and left in the re-
frigerator until use. Following incubation of diluted plas-
ma samples (1:50 in phosphate-buffered saline/albumin)
for 90 min at 37°C, plates were washed and incubated
with a peroxidase-labeled anti-human IgG antibody and
developed with o-phenylenediamine dihydrochloride. TheWillebrand factor parameters (VWF:Ag and VWF:Ac) at
s (d0) shows FVIII and VWF levels at initial presentation, while the
re the administration of 2,000 IU of FVIII/VWF concentrate, as
ce time of the infused FVIII/VWF, subsequent blood samples were
ministration. One day later (d4), immunosuppressive therapy with
apered to 20 mg on d31, as indicated by the solid arrows. One week
onded to re-escalating the prednisolone dose to 50 mg per day.
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off was defined as 2 x the OD of this plasma pool.
At presentation (day 0), we detected an anti-VWF IgG
antibody of 2.6 OD (normal range, <0.4 OD) [Figure 2A].
Importantly, addition of rhVWF to the patient plasma
completely blocked this reaction [data not shown], fur-
ther confirming specificity of the ELISA. Multimer ana-
lysis was carried out on a plasma sample obtained on
day 3, on which VWF parameters had spontaneously in-
creased to 15-25% [Figure 1], revealing the presence of
ultralarge VWF plasma multimers and absence of the
typical multimeric triplet structure [Figure 2B].
The patient received 2,000 IU of a VWF-containing
FVIII concentrate (Haemate® P, CSL Behring) on day 3.
While there was only a marginal and short-lasting incre-
ment in FVIII:C, VWF:Ag and VWF:Ac increased to
114% and 86%, respectively, and temporarily steadied at
these levels for 24 hrs before declining back to 34-41%
on day 5 [Figure 1].
Further diagnostic work-up revealed Coombs-positive
hemolytic anemia (hemoglobin, 12.3 g/dL) and high-
titer antinuclear antibodies (ANAs) at >1:5,120 (normal
range, <1:80) with a fine-speckled staining pattern. Anti-
double-stranded DNA antibodies and antibodies to
extractable nuclear antigens were negative, while IgG
antibodies to cardiolipin and β2-glycoprotein-I were
significantly increased to 256 U/mL and 564 U/mL,
respectively (normal ranges, <10 U/mL). Furthermore,Figure 2 Results of the in-house ELISA for the detection of anti-VWF-
VWF derived from CHO cells was used to measure IgG autoantibodies to V
OD during effective prednisolone therapy (day 31). A steep decline in VWF
20 mg a week earlier was accompanied by a temporary increase in the ant
titer had decreased to 0.6 OD, but was still above the reference range of th
of prednisolone, presence of unusually large VWF plasma multimers (arrows)
proteolysis of newly released, but rapidly cleared VWF (day 3). The multimeric
prednisolone (day 24). A high-resolution 1.6% agarose gel (left four lanes) and
better migration of the larger multimers into the gel, are shown. Different dilu
high-resolution gel. NHP denotes normal human plasma.the patient had a mild decrease in complement C3 of
79 mg/dL (normal range, 90-180 mg/dL) and borderline
lymphocytopenia of 21.7% (normal range, 20-45%). A
dilute Russell’s viper venom time for the detection of
lupus anticoagulant was 38 sec (normal range, 30-40 sec),
while the results of an APTT-based assay were inconclu-
sive, probably due to the FVIII inhibitor [13].
Computed tomography of the chest and abdomen ex-
cluded an underlying malignancy. Thus the diagnosis of
“late-onset SLE” was made based on the following clinical
and laboratory criteria [14]: skin rash, Coombs-positive
hemolytic anemia, positive antiphospholipid antibodies
and ANAs, lymphocytopenia, and C3 decrease.
Immunosuppressive therapy with prednisolone was ini-
tiated on day 4 at a daily dose of 100 mg, which resulted
in rapid elevations of VWF:Ag and VWF:Ac within four
days and a more delayed recovery of FVIII:C to normal
levels within 13 days into treatment [Figure 1]. Normali-
zation of VWF parameters was accompanied by the loss
of ultralarge plasma multimers and appearance of typical
VWF triplets on day 24 [Figure 2B]. Moreover, the anti-
FVIII- and anti-VWF-IgG titers decreased to 0.21 OD and
0.8 OD, respectively, on day 31.
The daily prednisolone dose was gradually tapered and
reduced to 20 mg on day 31, which resulted in a sharp
decline of VWF:Ag, VWF:Ac, and FVIII:C one week later
[Figure 1] and was accompanied by a temporary increase
in the anti-FVIII- and anti-VWF-IgG titers to 0.63 ODIgG and multimer analysis. (A) Immobilized recombinant human
WF. The titer was 2.6 OD at presentation (day 0) and decreased to 0.8
on day 38 following reduction of the daily prednisolone dose to
i-VWF-IgG titer to 1.2 OD on day 45. After six months of follow-up, the
e ELISA as indicated by the shaded red area. (B) Before the initiation
and absence of typical VWF triplets (arrow heads) indicated decreased
pattern normalized during effective immunosuppressive therapy with
a low-resolution 1.2% agarose gel (right two lanes), which allows for
tions of the patient plasma obtained on day 3 are indicated in the
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idly responded to re-escalating the daily prednisolone dose
to 50 mg on day 38.
Azathioprine and hydroxychloroquine were added at
daily doses of 50 mg and 200 mg, respectively, to spare
corticosteroids and maintain remission. However, azathi-
oprine had to be discontinued after one month due to
suspected drug fever. In addition, hydroxychloroquine
was discontinued ten weeks later based on the patient’s
preference and more non-specific side effects such as
myalgia, dizziness, and general discomfort. Nevertheless,
the prednisolone dose could be gradually tapered to a
maintenance dose of 5 mg per day. At the latest follow-
up, exactly one year after the initial presentation, the pa-
tient was still in complete remission with regard to his
acquired bleeding disorders.
Discussion
Here, we describe the case of an elderly patient with ac-
quired inhibitors against both FVIII and VWF. To the
best of our knowledge, a similar case has not been pre-
viously reported. Intriguingly, clinical and laboratory
work-up revealed “late-onset SLE” as the most prob-
able underlying condition. Development of this auto-
immune disorder in a 71-year-old man in itself represents
a quite unusual observation.
Typical clinical symptoms of AHA include spontan-
eous (muco)cutaneous and soft-tissue bleeding such as
observed in our patient. AHA is characterized by a pro-
longed APTT due to isolated FVIII deficiency that can-
not be corrected by mixing with normal human plasma.
The diagnosis is confirmed by the detection of a FVIII
inhibitor by either Bethesda assay or ELISA [15]. Our
patient, however, not only presented with severely de-
creased FVIII:C, but also with dramatically reduced plas-
ma VWF. In fact, based on the constellation of these
parameters, we initially suspected AVWS due to mono-
clonal gammopathy as the most likely diagnosis. In this
hemostatic disorder, the primary pathophysiological event
is rapid clearance of plasma VWF by a yet not completely
understood mechanism, while the decrease in circulating
FVIII is secondary to depletion of its carrier protein, VWF
[3]. Consequently, FVIII:C is usually responsive to ex vivo
mixing with normal human plasma. Interestingly, our in-
house ELISA did not detect anti-VWF-IgG in 14 patients
with AVWS due to IgG monoclonal gammopathy of
unknown significance (MGUS) [12], suggesting that the
paraprotein itself does not (always) function as a cir-
culating VWF inhibitor. In our patient, the severely
decreased FVIII:C in the presence of only moderately
decreased VWF levels on day 3 may also be considered
unusual for MGUS-associated AVWS. Finally, a monoclo-
nal paraprotein was ruled out by serum immunofixation
in our patient.Using a modified Bethesda assay, we could not detect
any functional interference of the IgG autoantibody with
VWF binding to immobilized collagen [data not shown].
A shortened half-life with accelerated clearance of the
antibody-opsonized VWF by the reticuloendothelial sys-
tem was thus the most plausible mechanism of VWF de-
pletion in our patient. The findings of multimer analysis
may be supportive of this hypothesis, because the pres-
ence of ultralarge plasma multimers and the absence of
typical triplets on day 3 are consistent with decreased
ADAMTS13-mediated proteolysis of massively released,
but rapidly cleared VWF [Figure 2B]. In this regard,
however, the effect of FVIII/VWF substitution on day 3
warrants closer attention.
The plasma-derived FVIII/VWF concentrate (Haemate®
P) was dosed according to its FVIII:C content. Conse-
quently, the patient received 2,000 IU of FVIII:C and
approximately 4,800 IU of VWF:RCo, the latter of which
corresponded to a body weight-adjusted dose of 60-
65 IU/kg. Assuming an increase in plasma VWF of 1-2%
per each IU infused per kg of body weight in patients
with congenital von Willebrand disease, the recovery
observed on day 3 appears adequate. Furthermore, the
subsequent decline in VWF parameters is consistent
with a half-life of up to 24 hrs. In fact, VWF parameters
appeared to stabilize for almost a day at 100% before de-
clining back to <50% two days after the administration
of FVIII/VWF concentrate. These findings clearly sug-
gest that the patient’s IgG autoantibody accelerated
clearance of self-produced VWF, while it did not affect
the purified plasma-derived VWF present in Haemate® P.
FVIII:C showed only a marginal response to FVIII/
VWF substitution, a finding characteristic for AHA and
further supporting our conclusion that the patient had
two distinct immune responses, one against FVIII and
one against VWF. Consistently, following initiation of
prednisolone therapy on day 4, VWF parameters nor-
malized within four days, while FVIII:C showed a more
delayed response with normal values not reached before
almost two weeks into treatment.
So far, only 16 cases of AVWS related to SLE have
been reported [3,10,11,16]. In these patients, different
patterns of VWF plasma multimers have been observed.
While loss of larger plasma multimers was documented
in six patients, corresponding to a type-2 pattern [3,10],
multimers were completely absent in two patients [3],
corresponding to a type-3 pattern. In our patient, first
multimer analysis was carried out on day 3, on which
VWF parameters had spontaneously increased from <5%
to 15-25%. While a type-2 pattern could be ruled out at
first sight, the presence of a condensed band at exceed-
ingly high molecular weight suggested the presence of
ultralarge VWF plasma multimers. This finding was con-
firmed using a low-resolution agarose gel [Figure 2B].
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described in patients with thrombotic-thrombocytopenic
purpura (TTP) in whom endothelium-derived VWF is
not processed due to an inherited or acquired deficiency
of the VWF-cleaving metalloproteinase, ADAMTS13
[17]. Consistent with a similar mechanism of decreased
ADAMTS13-mediated VWF cleavage in our patient, pro-
teolytic subbands accounting for the typical multimeric
triplet structure were absent at presentation, but appeared
following remission induction. We hypothesize that rapid
clearance of the newly released VWF by the IgG autoanti-
body prevented its proper proteolytic processing. Massive
release of VWF, which is likely to occur in SLE pa-
tients due to an acute-on-chronic inflammation of the
vascularized connective tissue [18], may have tempor-
arily overruled the clearing kinetics of the IgG autoanti-
body, allowing for visualization of the slightly increased
VWF on day 3. Additionally (or alternatively), binding
of the autoantibody to VWF may have conferred steric
hindrance, thereby inhibiting proper enzyme-substrate in-
teractions. In this regard, the condensed high-molecular-
weight band may be composed of, or at least contain,
IgG-VWF immune complexes. However, normal migra-
tion of the low and intermediate sized plasma multi-
mers may argue against this hypothesis. Nevertheless,
studies addressing these issues are currently ongoing
in our laboratory.
Previous studies on the presence of VWF autoanti-
bodies using immunoassays with immobilized plasma-
derived VWF have been prone to false-positive results
due to cross-reactivity of plasma isoagglutinins with ABO
blood group antigens present on VWF [19]. To improve
specificity, we have developed an in-house ELISA with
rhVWF derived from the transfected mammalian, but
non-human CHO cell line. Interestingly, eleven out of 112
healthy blood donors (10%) were tested positive with ODs
of 0.4-0.6. Since reactions could be blocked by exogenous
addition of VWF, signals seemed to be specific for anti-
VWF-IgG. As expected, there was no ABO blood group
dependency of this reaction [12].
Considering that the patient had two severe and po-
tentially life-threatening bleeding disorders, AHA and
AVWS, the hemorrhagic phenotype may be judged as
quite moderate. In this regard, it could be speculated
that the concomitant presence of elevated antiphospholi-
pid antibodies partially counterbalanced the patient’s
bleeding diathesis through the promotion of a thrombo-
genic state [20,21].
Conclusion
In summary, about 45 years after its first description in a
12-year-old boy with SLE, we describe another unusual
case of AVWS in an elderly patient with “late-onset
SLE”. Although FVIII specifically binds to VWF withinthe circulation, to our knowledge this is the first case re-
port describing concomitant autoimmune-mediated AHA
and AVWS in a single patient.
In patients with suspected AHA, laboratory assess-
ment of circulating VWF (i.e. through quantification of
its antigen and activity levels) may be regarded as com-
mon clinical practice to rule out AVWS as an alternative
diagnosis. Based on our experience, however, the future
diagnostic work-up of patients with AVWS and severely
reduced plasma FVIII should also include specific im-
munologic (i.e. ELISA) or functional inhibitor tests (i.e.
mixing study or Bethesda assay) to safely exclude con-
comitant AHA.
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